# Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

> **NCT00041925** · PHASE2,PHASE3 · COMPLETED · sponsor: **Anesiva, Inc.** · enrollment: 1400 (—)

## Conditions studied

- Peripheral Vascular Diseases
- Arterial Occlusive Diseases
- Ischemia
- Graft Occlusion, Vascular
- Hyperplasia

## Interventions

- **DRUG:** CGT003 (E2F Duplex Decoy)

## Key facts

- **NCT ID:** NCT00041925
- **Lead sponsor:** Anesiva, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** 1400 (—)
- **Last updated:** 2005-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041925, "Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00041925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*